Ms. Yue Wang United States

Single cell multi-omics company to eradicate cancer
Website:
Missionbio.com
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
To expand user base and market
Headquartner in China
MissionBio
Fas 
Functionality

J. Gene WANG United States

Immetas discovers and develops novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The company’s approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases, and anchored in clinical evidence to mitigate development risk. Immetas was founded by J. Gene Wang, MD, PhD, a veteran in discovery and translational drug development in immunology/ inflammation and oncology, and David Sinclair, PhD, Professor of Genetics at Harvard Medical School and a leader in the molecular mechanisms of aging. The lead program in the company’s growing pipeline is focused on engineering bispecific antibodies to modulate inflammation in the tumor microenvironment and overcome resistance to the conventional immune checkpoint therapies. Learn more at www.immetas.com
Partnering Objectives
Headquartner in China
Immetas Therapeutics
CEO 

bingwen wang United States

Top American medical device company
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Boston Scientific
physician 

Renfei WANG United States

Website:
www.huyabio.com
Partnering Objectives
Please specify your partnering goal
To find new projects of interest
Headquartner in China
HUYA BIOSCIENCE INTERNATIONAL
Scientific liaison manager 

Max Wang United States

Our mission is very simple: to use immunology to save the lives of the most vulnerable. Whether it’s the young who have yet to develop strong immune systems, the elderly who suffer from waning immune systems, or the immunocompromised whose immune systems are insufficient do to acquired medical conditions or the treatments thereof, Ansun’s mission is to discover and use novel approaches to develop therapies that prevent, treat, and cure some of the world’s most vexing human diseases. This has been our mission since 2003, when Ansun was formed for the purpose of developing a novel approach to treat otherwise untreatable pandemic flu strains (in fact, all flu strains), and it remains our mission today.
Company Size (Fulltime employees)
Please specify your partnering goal
BD
Headquartner in China
Ansun Biopharma
BD 

Dr. Zongxing Wang United States

VC in Chicago
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
just check out
Headquartner in China
ARCH Venture Partners
Investor 

Mr. Jason Wang United States

Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.
Website:
adverum.com
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
N/A
Headquartner in China
Adverum Biotechnologies
Associate Director Strategy 

Dr. Hong Wang United States

Pharmaceutical company
Website:
www.luye.com
Company Size (Fulltime employees)
Please specify your partnering goal
License in
Headquartner in China
Biotech/Pharma Asset Stage
Medtech Development Stage
Luye
Senior investigator 

Mark Wesson United States

CUBIO Innovation Center
Mentor, Chief Financial Officer 

Margaret Wong United States

CUBIO Innovation Center
Mentor, Regulatory/Compliance Advisor